Jun 16, 2021 / 02:00PM GMT
Jason Butler - JMP Group LLC - Analyst
Great. Good morning and welcome to the JMP Securities' life sciences conference. I am Jason Butler, Senior Biotechnology Analyst. Welcome, everybody. Really excited to kick things off this year with Minerva Neurosciences, where we are joined this morning by Remy Luthringer, the Company's CEO. Remy, great to see you; great to have you here.
Minerva is focused on the development of novel therapies for unmet needs in neuroscience, and specifically, their lead candidate, roluperidone, has completed a Phase III trial in patients with negative symptoms of schizophrenia. The Company is working towards FDA interactions towards an NDA submission.
And so we again welcome Remy. We'd love to just have a -- you give a quick intro and maybe just give us a little bit of the background of roluperidone and how you see the asset fitting into the unmet need. Thank you.
Remy Luthringer - Minerva Neurosciences, Inc. - Executive Chairman & CEO
Thank you so much, Jason. Yes, and really thank you for having us and having me,
Minerva Neurosciences Inc at JMP Securities Life Sciences Virtual Conference Transcript
Jun 16, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers